Search results for "Musculoskeletal"

showing 10 items of 1714 documents

Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo I…

2020

Abstract Background Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually affecting young adults. Interestingly, recent evidence from the juvenile counterpart of AOSD suggested the emergent high fatality rate of lung disease (LD) in these patients. In this work, we aimed to characterise LD in AOSD, to identify associated clinical features and predictive factors, and to describe long-term outcomes of the disease comparing patients with LD and those without. Methods A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was provided to describe the rate of LD in AOSD, associated clinical features and pre…

Lung DiseasesmyalgiaAbdominal painmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemDiseaseSeverity of Illness IndexYoung AdultAdult onset Still's diseaseInternal medicineCase fatality ratemedicineHumansMortalityYoung adultSurvival rateAgedRetrospective StudiesAdult onset Still’s diseasebusiness.industryMortality rateAdult onset Still's disease; Lung disease; MortalityLung diseaseCohortMortality.lcsh:RC925-935medicine.symptombusinessStill's Disease Adult-OnsetBiomarkersResearch ArticleArthritis Research & Therapy
researchProduct

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct

Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts.

2010

Gallium (Ga) has been shown to be effective in the treatment of disorders associated with accelerated bone loss, including cancer-related hypercalcemia and Paget's disease. These clinical applications suggest that Ga could reduce bone resorption. However, few studies have studied the effects of Ga on osteoclastic resorption. Here, we have explored the effects of Ga on bone cells in vitro.In different osteoclastic models [osteoclasts isolated from long bones of neonatal rabbits (RBC), murine RAW 264.7 cells and human CD14-positive cells], we have performed resorption activity tests, staining for tartrate resistant acid phosphatase (TRAP), real-time polymerase chain reaction analysis, viabili…

MESH: Bone ResorptionMESH: RabbitsGallium[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]MESH: Base Sequence[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyMiceMESH: Alkaline PhosphataseMESH: Reverse Transcriptase Polymerase Chain Reaction[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]MESH: Animals[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Cells Cultured[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemReverse Transcriptase Polymerase Chain ReactionCell DifferentiationMESH: GalliumResearch Papers[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]Isoenzymes[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemMESH: Isoenzymes[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]RabbitsMESH: Cells Culturedmusculoskeletal diseasesMESH: Cell DifferentiationMESH: DNA PrimersAcid Phosphatase[SDV.CAN]Life Sciences [q-bio]/CancerIn Vitro TechniquesMESH: Acid Phosphatase[SDV.CAN] Life Sciences [q-bio]/Cancer[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]AnimalsHumansBone Resorption[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]MESH: Tartrate-Resistant Acid Phosphatase[SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/BiomaterialsMESH: MiceDNA PrimersMESH: In Vitro TechniquesMESH: OsteoblastsOsteoblastsMESH: HumansBase SequenceTartrate-Resistant Acid Phosphatase[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyAlkaline Phosphatase[SDV.IB.BIO] Life Sciences [q-bio]/Bioengineering/Biomaterials
researchProduct

3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells

2014

Objective Growing evidences indicate that the histone methyltransferase EZH2 (enhancer of zeste homolog 2) may be an appropriate therapeutic target in some tumors. Indeed, a high expression of EZH2 is correlated with poor prognosis and metastasis in many cancers. In addition, 3-Deazaneplanocin A (DZNep), an S-adenosyl-L homocysteine hydrolase inhibitor which induces EZH2 protein depletion, leads to cell death in several cancers and tumors. The aim of this study was to determine whether an epigenetic therapy targeting EZH2 with DZNep may be also efficient to treat chondrosarcomas. Methods EZH2 expression was determined by immunohistochemistry and western-blot. Chondrosarcoma cell line CH2879…

MESH: Cell DeathAdenosine[SDV]Life Sciences [q-bio]Cancer Treatmentlcsh:MedicineMESH: Flow CytometryApoptosischemistry.chemical_compoundSpectrum Analysis Techniques0302 clinical medicineCell MovementMolecular Cell BiologyMedicine and Health Sciences3-Deazaneplanocin AMESH: Epigenesis GeneticEnzyme Inhibitorslcsh:Science0303 health sciencesMultidisciplinaryCell DeathbiologyReverse Transcriptase Polymerase Chain ReactionEZH2Polycomb Repressive Complex 2DrugsCell migrationMESH: ChondrosarcomaFlow Cytometry3. Good healthHistone[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemOncologyConnective TissueCell ProcessesSpectrophotometry030220 oncology & carcinogenesisHistone methyltransferaseHistone MethyltransferasesMESH: 3-deazaneplanocinCytophotometryAnatomyMESH: Polycomb Repressive Complex 2Epigenetic therapyMESH: Histone methyltransferaseResearch ArticleProgrammed cell deathHistologyChondrosarcoma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular Biologymacromolecular substancesResearch and Analysis MethodsCell GrowthEpigenetic Therapy03 medical and health sciencesRheumatologyCell Line TumorMESH: Blotting WesternHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyEZH2Tumors030304 developmental biologyMESH: Apoptosislcsh:RMESH: Histone-Lysine N-MethyltransferaseBiology and Life SciencesMESH: ImmunohistochemistryHistone-Lysine N-MethyltransferaseCell BiologyBiological TissueCartilageHistone methyltransferasechemistryApoptosisbiology.proteinCancer researchMESH: EZH2 protein humanlcsh:QCytometry
researchProduct

Associations of neck muscle strength and cervical spine mobility with future neck pain and disability: a prospective 16-year study.

2021

Abstract Background Neck pain has been associated with weaker neck muscle strength and decreased cervical spine range of motion. However, whether neck muscle strength or cervical spine mobility predict later neck disability has not been demonstrated. In this 16-year prospective study, we investigated whether neck muscle strength and cervical spine mobility are associated with future neck pain and related disability in women pain-free at baseline. Methods Maximal isometric neck muscle strength and passive range of motion (PROM) of the cervical spine of 220 women (mean age 40, standard deviation (SD) 12 years) were measured at baseline between 2000 and 2002. We conducted a postal survey 16 ye…

MOTIONSports medicine2000-2010 TASK-FORCEneck painliikeradatlihaksetkaularankaDiseases of the musculoskeletal systemPromIsometric exerciseLOW-BACKkivunhoito0302 clinical medicineNeck disabilityNeck MusclesMedicineOrthopedics and Sports Medicine030212 general & internal medicineProspective StudiesRange of Motion ArticularProspective cohort studyChildRange of motionINDEX2. Zero hungerNeck painNeck PainPHYSICAL CAPACITYRANGEniskaWOMENWORKERSCervical VertebraeFemalemedicine.symptomRange of motionneck disabilitymedicine.medical_specialtySHOULDER PAINrange of motionAssociation03 medical and health sciencesRheumatologyHumansbusiness.industryMuscle strengthResearchassociationkipu3126 Surgery anesthesiology intensive care radiologyRC925-9353121 General medicine internal medicine and other clinical medicineOrthopedic surgerymuscle strengthRISK-FACTORSPhysical therapybusinessBody mass index030217 neurology & neurosurgerylihasvoimaBMC musculoskeletal disorders
researchProduct

Rats bred for low aerobic capacity become promptly fatigued and have slow metabolic recovery after stimulated, maximal muscle contractions.

2012

AIM. Muscular fatigue is a complex phenomenon affected by muscle fiber type and several metabolic and ionic changes within myocytes. Mitochondria are the main determinants of muscle oxidative capacity which is also one determinant of muscle fatigability. By measuring the concentrations of intracellular stores of high-energy phosphates it is possible to estimate the energy production efficiency and metabolic recovery of the muscle. Low intrinsic aerobic capacity is known to be associated with reduced mitochondrial function. Whether low intrinsic aerobic capacity also results in slower metabolic recovery of skeletal muscle is not known. Here we studied the influence of intrinsic aerobic capac…

Magnetic Resonance SpectroscopyAnatomy and PhysiologyPhosphocreatineEvolutionary Selectionlcsh:MedicineIsometric exerciseBreedingmetaboliset sairaudetBiochemistrychemistry.chemical_compound0302 clinical medicineTriceps surae muscleMyocyteta315lcsh:ScienceMusculoskeletal System0303 health sciencesMultidisciplinarycomplex diseaseMuscle BiochemistryAnatomyAnimal ModelsHydrogen-Ion Concentrationmedicine.anatomical_structureaerobinen kapasiteettiMuscle FatigueMuscleaerobinen suorituskykymedicine.symptomMuscle contractionMuscle ContractionResearch Articlemedicine.medical_specialtyEvolutionary ProcessessupistusominaisuudetBioenergeticsPhosphocreatinePhosphates03 medical and health sciencesModel OrganismsInternal medicinePhysical Conditioning AnimalmedicineGeneticsAnimalsskeletal muscleAdaptationBiologyAerobic capacity030304 developmental biologyEvolutionary BiologyMuscle fatiguelcsh:RSkeletal muscleElectric StimulationRatsraajalihasEndocrinologyMetabolismcontractile propertieschemistryRatlcsh:QEnergy MetabolismPhysiological ProcessesAnimal Genetics030217 neurology & neurosurgeryPLoS ONE
researchProduct

Preoperative Considerations on the Thorax: Anatomy and Surgical Landmarks

2020

The thoracic wall is the higher part of the thorax consisting of a musculoskeletal structure including the mediastinum, the pleuropulmonary cavities, viscera, lymphatic, vascular, and nervous structures. Its dimensions are influenced by age, gender, and life style including physical training. It changes constantly in shape and size according to respiration: Generally, males show an abdominal pattern while females have usually a thoracic respiration pattern. The anatomy of the chest differs between men and women, with considerable variations among different ages and races. The skin is thicker in male than in female. In the male thorax, hair is frequently present and the mammary glands are un…

Male chest wall anatomyThoraxRib cagebusiness.industryMale mammary regionSynchondrosisMediastinumAnatomyThoraxmusculoskeletal systemXiphoid processChest wall anatomymedicine.anatomical_structureClavicleMedicineAbdomenbusinessMale pectoral regionThoracic wall
researchProduct

Sex Differences in the Neuroadaptations of Reward-related Circuits in Response to Subchronic Variable Stress

2018

Women are twice as likely to be diagnosed with major depressive disorder. However, fewer studies in rodent models of depression have used female animals, leading to a relative lack of understanding of the female brain’s response to stress, especially at a neural circuit level. In this study, we utilized a 6-day subchronic variable stress (SCVS) mouse model and measured novelty suppressed feeding as behavioral criteria to evaluate susceptibility to SCVS in male and female mice. First, we showed that SCVS induced a decrease in latency to eat (susceptible phenotype) in female mice, but not in males (resilient phenotype). After determining behavioral phenotypes, we investigated the firing activ…

Male0301 basic medicineAction Potentialsneuronal activityTissue Culture Techniques0302 clinical medicinePremovement neuronal activitylocus coeruleuNeuronsSex CharacteristicsNeuronal Plasticitymusculoskeletal neural and ocular physiologyGeneral NeuroscienceBrainPhenotypeVentral tegmental areamedicine.anatomical_structureMajor depressive disorderFemaleDisease Susceptibilitylateral habenulamedicine.drugmedicine.medical_specialtyCell typesex differenceventral tegmental areaBiologyArticle03 medical and health sciencesRewardDopamineInternal medicinemedicineAnimalsAction PotentialDepressive DisorderAnimalNeuronmedicine.diseaseMice Inbred C57BLElectrophysiology030104 developmental biologyEndocrinologynervous systemSettore BIO/14 - FarmacologiaLocus coeruleusTissue Culture Techniquemajor depressionStress Psychological030217 neurology & neurosurgeryNeuroscience
researchProduct

THE USE OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (ANAKINRA) IN KAWASAKI DISEASE: A RETROSPECTIVE CASES SERIES

2018

Introduction: Persistent fever and inflammation after infusion of 2g/kg of IVIG, the standard treatment of KD represents a high-risk situation for coronary aneurysms in Kawasaki disease. Identifying patients at risk for IVIG resistance is difficult outside the Asian population, and there remains a critical unmet need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Recent evidence from studies in animals and humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. Objectives: To identify the clinical characteristics, reasons for use and response to treatment with anakinra in a retrospective series of patients with Kawasaki …

Male0301 basic medicineBLOCKADEPlacebo-controlled studyCHILDRENSUSCEPTIBILITYPLACEBO-CONTROLLED TRIALPediatricsDOUBLE-BLIND0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieINTERLEUKIN 1 RECEPTOR ANTAGONIST ANAKINRA KAWASAKI DISEASEImmunology and AllergyJUVENILE IDIOPATHIC ARTHRITISChildPediatricAnakinra coronary artery aneurysmPrognosis1107 ImmunologyChild PreschoolDisease ProgressionFemaleVasculitisLife Sciences & BiomedicineHumanmedicine.drugVasculitismusculoskeletal diseasesAutoinflammatory diseaseVasculitimedicine.medical_specialtyMyocarditisPrognosiImmunologyMucocutaneous Lymph Node SyndromeAnakinra coronary artery aneurysms03 medical and health sciencesInternal medicineINFLIXIMABMANAGEMENTmedicineINTRAVENOUS IMMUNOGLOBULINHumansRetrospective Studies030203 arthritis & rheumatologyAnakinraScience & TechnologyKawasaki diseasebusiness.industryInfantReceptors Interleukin-1Retrospective cohort studymedicine.diseaseInfliximabInterleukin 1 Receptor Antagonist Protein030104 developmental biologyInterleukin 1 receptor antagonistKawasaki diseasebusinessInterleukin-1
researchProduct